中国批准对高级肝癌进行新的药物组合,有望提高存活率。 China approves new drug combo for advanced liver cancer, promising better survival rates.

上海Junshi生物科学药物tripalimab(用于乙型肝癌)经中国国家精神和健康局批准,用于治疗高级肝癌。 Shanghai Junshi Biosciences' drug toripalimab, when used with bevacizumab, has been approved by China's NMPA for treating advanced liver cancer. 根据HEPATOORCH研究,与Sorafenib标准治疗相比,这种结合大大改善了无进展和总体存活率。 Based on the HEPATORCH study, the combination significantly improved progression-free and overall survival compared to standard treatment with sorafenib. 这项批准旨在惠及中国许多肝癌患者,那里的肝癌病例和死亡率很高。 This approval aims to benefit many advanced liver cancer patients in China, where liver cancer cases and deaths are high.